Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed-Reference-Cited by-同舟云学术

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

Published:2014-09 Issue:3 Volume:147 Page:618-627.e3
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Sands Bruce E.,Feagan Brian G.,Rutgeerts Paul,Colombel Jean-Frédéric,Sandborn William J.,Sy Richmond,D’Haens Geert,Ben-Horin Shomron,Xu Jing,Rosario Maria,Fox Irving,Parikh Asit,Milch Catherine,Hanauer Stephen

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference36 articles.

1. Crohn's disease;Baumgart;Lancet,2012

2. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management;Dignass;J Crohns Colitis,2010

3. Natalizumab for active Crohn's disease;Ghosh;N Engl J Med,2003

4. Management of Crohn's disease in adults;Lichtenstein;Am J Gastroenterol,2009

5. Natalizumab induction and maintenance therapy for Crohn's disease;Sandborn;N Engl J Med,2005

Cited by 595 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Maintenance Immunosuppression in Intestinal Transplantation;Gastroenterology Clinics of North America;2024-09

2. Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review;Biologics;2024-08-30

3. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins;The Korean Journal of Gastroenterology;2024-08-25

4. Optimization of transplantation methods using isolated mesenchymal stem/stromal cells: clinical trials of inflammatory bowel diseases as an example;Inflammation and Regeneration;2024-08-16

5. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08